RP 6530

Drug Profile

RP 6530

Alternative Names: RP6530

Latest Information Update: 09 May 2017

Price : $50

At a glance

  • Originator Rhizen Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Haematological malignancies; T cell lymphoma
  • Preclinical Ovarian cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from in vitro studies in Ovarian cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 03 Dec 2016 Pharmacodynamics data from in vitro and preclinical studies in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 03 Dec 2016 Efficacy, safety and pharmacokinetics data from a phase I trial in Haematological malignancies (Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top